A b s t r a c t
Assays for D-dimer are widely used in the evaluation of patients with suspected venous thromboembolism or disseminated intravascular coagulation. These assays have been introduced in the absence of standardized units of measure and without a program to ensure that laboratory professionals and clinicians understand in which clinical situations they inform practice.
As a component of an ongoing proficiency testing program mandated by provincial legislation, the Quality Management Program -Laboratory Services (QMP-LS), Toronto, Canada, provides samples for external quality assessment (EQA) twice a year to Ontario laboratories licensed to perform D-dimer testing. In 2004, QMP-LS distributed D-dimer survey material for EQA in cooperation with the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. The survey material consisted of lyophilized plasma containing human-derived D-dimer diluted to produce varying levels of D-dimer. This exercise confirmed wide variability in testing practices, varying D-dimer kit sensitivities, and the use of multiple units of measure. 1 Pooled human-derived D-dimer is not ideal material for EQA because it is difficult to access, may be contaminated with biologic agents, is not commercially available, and contains varying levels of multiple breakdown products of fibrino(geno)lysis. 1 Although EQA systems that use these materials are able to monitor the ability of users and manufacturers to detect breakdown products of fibrino(geno)lysis, they are not able to reliably determine the accuracy with which D-dimer itself is measured.
A favorable material for EQA exercises would be a human-derived D-dimer prepared from purified protein components, which could then be spiked into plasma to produce known D-dimer concentrations and lyophilized to facilitate storage and shipment. The advantage of the use of a purified product is the fact that kits evaluated using human-derived nonpurified D-dimer should have reasonable within-method consensus, but poor between-method consensus because the kits variably measure products of fibrino(geno)lysis; as a result, different kits will produce different results on a common plasma sample. A purified D-dimer, which contains predominantly a single product of lysis, should produce similar results across all kits if they are able to measure D-dimer in a reliable manner. This allows result comparison within methods, between methods, and over time. Purified D-dimer overcomes the problem of varied results due to method and constituents present and allows for consistent evaluation of performance by EQA programs.
QMP-LS approached Affinity Biologicals, Hamilton, Canada, to determine if it could manufacture testing material suitable for EQA. After a developmental period, the requested material was prepared, and the QMP-LS subsequently used this survey material in 4 EQA surveys. We present the results of these surveys.
D-dimer results are generally reported as D-dimer units (DDU) or fibrinogen equivalent units (FEU), which reflect the amount of D-dimer present and the method used to capture and "read-out" the quantity of D-dimer. Kits reporting in FEU find concentrations of D-dimer that are approximately twice those reported by kits reporting in DDU. For the purposes of this article, DDU were converted to Système International (SI) units: fibrin D-dimer units DDU (µg/L) or fibrin D-dimer FEU (µg/L).
Materials and Methods
All licensed medical laboratories in Ontario are mandated to participate in the EQA program of the Ontario QMP-LS. Participants include hospital-and community-based laboratories with varying capabilities, size, and sample throughput. Participants are required to analyze samples and report their results to the QMP-LS. The results are reviewed, analyzed, and scored. Participants reporting unexpected or discordant results are asked to investigate and explain the root cause of the discrepant result.
In preparation for this work, the QMP-LS performed a patterns-of-practice survey to better understand preanalytic, analytic, and postanalytic laboratory practices for D-dimer testing. The 4 surveys described in this report were composed of samples containing varying levels of commercially prepared D-dimer and "normal D-dimer" samples. Normal D-dimer plasma concentrations were defined as those present in a pool of normal citrated human plasma from 20 healthy donors. Buffers and stabilizers were added to the pool, and it was immediately divided into aliquots and lyophilized. For "high D-dimer" samples, Affinity Biologicals provided D-dimer testing material prepared from a limited digest of a cross-linked fibrin clot from purified components. The lysate, with a known D-dimer level, was then added to the normal citrated plasma pool to achieve the predetermined final D-dimer concentration. Buffers and stabilizers were added to the plasma samples, which were immediately divided into aliquots and lyophilized. Recovery and quantification for the purposes of comparison were determined by using the IL HemosIL D-dimer test kit, Instrumentation Laboratories, Lexington, MA. Recovery of D-dimer postlyophilization was approximately 104% to 107% of the theoretical valuethe elevation above 100% was due to expected variation in the assay used to measure recovery.
In addition to quantitative and semiquantitative D-dimer assays, a variety of qualitative whole blood assays for D-dimer are available and in widespread clinical use. To participate in this EQA exercise, participants using whole blood D-dimer methods were asked to add an equal volume of a 75% suspension of washed group O RBCs to the reconstituted plasma sample and analyze the sample for D-dimer in a routine manner. A disclaimer was included in the survey instructions stating that the manufacturers of red cell agglutination D-dimer kits do not recommend the addition of cells to test plasma samples and that this procedure was to be used only for EQA purposes. 2 Two surveys (A and B) were distributed in February and September 2006, and 2 other surveys (C and D) were distributed in February and September of 2007.
In the pilot survey, participants were requested to perform routine testing and report the quantitative level of D-dimer in their usual unit of measure. In following surveys, to reduce confusion and facilitate analysis, participants were required to report quantitative results in 1 of 2 SI units, fibrin D-dimer DDU (µg/L) or fibrin D-dimer FEU (µg/L). zTable 1z illustrates examples of converting to micrograms per liter to assist with this request. Results were required within 9 working days of receipt. Participants were not to collaborate on testing, and results were returned by facsimile to the QMP-LS office. 
Results
The number of laboratories taking part in the 4 D-dimer surveys were 125, 129, 130, and 129, respectively. The supplier's results, number of participants, and participants' results according to the manufacturer and kit used are given in zTable 2z, zTable 3z, and zTable 4z.
In survey A, the supplier's results reported that vial 1 contained fibrin D-dimer DDU of 190 µg/L (mimicking normal levels) and vial 2 contained fibrin D-dimer DDU of 533 µg/L (mimicking moderately elevated levels, consistent with those likely to be found in a patient with venous thromboembolism). In survey B, the supplier's results indicated that vial 1 contained fibrin D-dimer DDU of 190 µg/L (mimicking normal levels) and vial 2 contained fibrin D-dimer DDU of 1,712 µg/L (mimicking elevated levels, as might be found in a patient with septicemia). In survey C, the supplier reported vial 1 contained fibrin D-dimer DDU of 1,582 µg/L (mimicking elevated levels) and vial 2 contained fibrin D-dimer DDU of 235 µg/L (mimicking normal levels). In survey D, the supplier reported that vial 1 contained fibrin D-dimer DDU of 528 µg/L (mimicking moderately elevated levels) and vial 2 contained fibrin D-dimer DDU of 185 µg/L (mimicking normal levels).
Given the lack of standardization of D-dimer assays 3 and reporting units and the lack of prior EQA D-dimer surveys in Ontario, our expectations of laboratory performance were limited. The first survey using this testing material was considered a pilot survey, and errors were not assessed. In the next 2 surveys, QMP-LS did not attempt to assess absolute D-dimer levels but rather assessed a laboratory's results based on the laboratory's ability to differentiate between normal and abnormal levels. For the fourth survey, the assigned value was determined as the consensus value from participants (mean) if 5 or more participants performed D-dimer analysis using a specific method (kit). After an extensive review, an allowable performance limit of ± 40% of the assigned value was considered, validated, and published. This rule, in addition to a laboratory's ability to differentiate between normal and abnormal levels, was used to assess the September 2007 survey. Of note, because many participants reported normal D-dimer responses as a less than value (ie, <n), an accurate deviation from the assigned value for the "normal" sample could not be determined.
In survey A, a total of 5 participants (4.0%; 95% confidence interval [CI], 1.3%-9.1%) reported incorrect responses. Of 57 laboratories using a qualitative assay, 2 (4%; CI, 0.4% to 12.1%) reported vials 1 and 2 as "positive," whereas another participant reported both vials as negative; of 21 laboratories reporting semiquantitative D-dimer assays, 3 (14%; CI, 3.0%-36.3%) were unable to detect the moderately elevated level of D-dimer in vial 2. All 56 participants reporting quantitative D-dimer assays were able to differentiate between normal levels of D-dimer and moderately elevated levels (rate of laboratories unable to differentiate, 0%; CI, 0.0%-6.4%).
In survey B, all laboratories reporting qualitative and semiquantitative D-dimer results reported the results for vial 1 within their normal reference interval or negative (0% error rate; CI, 0.0%-4.7%) and for vial 2 as greater than their normal reference interval or positive (0% error rate; CI, 0.0%-4.7%). Of 61 participants reporting quantitative D-dimer results, 1 (2%; CI, 0.0%-8.8%) erroneously reported an elevated level of D-dimer on vial 1. The follow-up investigation of the discordant finding noted that the laboratory reported the wrong unit value.
In survey C, a total of 3 participants (2.3%; CI, 0.5%-6.6%) provided incorrect responses. All laboratories reporting semiquantitative D-dimer results reported the expected results with vial 1 as greater than their normal reference intervals (0% error rate; CI, 0.0%-21.8%) and vial 2 as within their normal reference intervals (0% error rate; CI, 0.0%-24.7%). Of 58 participants reporting qualitative D-dimer results, 1 (2%; CI, 0%-9.2%) erroneously reported a positive D-dimer on vial 2, whereas 2 (3; CI, 0.4%-10.7%) of 65 participants reporting quantitative D-dimer results erroneously reported a normal level of D-dimer on vial 1. Of these 2 participants, 1 also incorrectly reported an elevated level of D-dimer on vial 2. Following investigation of the discordant finding, 1 laboratory reported a transcription error, 1 a technical error, and 1 noted testing of the wrong sample. Of note, 6 participants reported quantitative results for vial 2 that were slightly more than their reference intervals. These results were considered equivocal.
In survey D, a total of 3 (2.3%; CI, 0.4%-6.6%) laboratories provided incorrect responses. All participants reporting qualitative and semiquantitative D-dimer results reported the expected results with vial 1 as greater than their normal reference intervals and vial 2 as within their normal reference intervals (0% error rate; CI, 0.0%-5.1%). Of 76 participants reporting quantitative D-dimer results, 1 (1%; CI, 0%-7.1%) reported a result for vial 1 outside the allowable performance limit and 2 (3%; CI, 0.3%-9.2%) of 76 participants reporting quantitative D-dimer results on vial 2 reported results greater than their normal reference intervals.
Discussion
In these surveys, we used a human-derived D-dimer with known properties to assess the performance of laboratories Data are given as number of laboratories reporting correctly/number of participants reporting use of each method. † Six results were considered equivocal and not assessed an error. ‡ Allowable performance limits ± 40% in which 5 or more participants performed D-dimer analysis using a specific method (kit). § Investigation of discordant results revealed a transcription error.
in Ontario. We observed that participants were proficient in the analysis of these samples and were able to report reliable results using a common and limited set of units.
Our surveys represent a number of important firsts in this area. Previous EQA testing of D-dimer has used testing material that showed a large variation in results. 4, 5 To our knowledge, EQA testing for D-dimer has not previously been carried out using a well-characterized, artificially prepared D-dimer source material. Advantages of such a test system include predetermined D-dimer levels, reduced risk of pathogen transmission, and absence of other products of fibrino(geno)lysis that are measured in some commercial D-dimer assays. In addition, this material can be produced in sufficient quantities to allow large surveys and, perhaps, development of validated quality control material. Our work also confirms that EQA for participants using qualitative assays could be evaluated through the development of a test system in which "whole blood" was prepared by reconstitution of the test material in diluted packed RBCs. Before our experience, EQA testing for qualitative assays was often limited to availability of fresh whole blood samples.
In the first survey, we were concerned to observe that 3 of 21 participants using 3 different reagents reported an elevated D-dimer level as normal. The most likely explanation for this finding was that the D-dimer level (fibrin D-dimer DDU of 533 µg/L) in the "abnormal" sample was only moderately elevated. Future surveys should explore the performance characteristics of these assays in the moderately elevated range because these levels are often seen in patients with acute venous thromboembolism referred for D-dimer testing; thus a false-negative test result might inappropriately exclude venous thromboembolism. This observation also highlights the requirement that participants use assays that have been validated for individual clinical situations. Many commercial D-dimer assays (particularly the qualitative and semiquantitative kits) have not been validated for use in patients with suspected venous thromboembolism, have been validated only when used in concert with a clinical probability assessment tool, or have been shown to be insufficiently sensitive for clinical use. 6 The second, third, and fourth surveys demonstrated that participants could successfully convert their reporting units to a common SI D-dimer unit value, independent of the kit used. Currently, confusion exists for physicians in interpreting or comparing test results from laboratories using different methods for D-dimer testing, allowing the potential for medical error (as seen in survey B). Ideally, reporting of this test result should conform to SI nomenclature and a single component name (method of measure) be used.
Our results are limited by the scope of the QMP-LS EQA mandate because D-dimer survey material is distributed only twice per year. Given the infrequency of this testing, we are not able to assess day-to-day variability in results within or between laboratories. However, our ability to use a commercially prepared, quantifiable, and reproducible D-dimer reagent suggests that such a reagent would be useful in day-to-day quality control exercises. Availability of such a reagent would represent an important step in laboratory quality procedures given the current lack of reliable, widely available test materials.
Our results suggest that a technically competent and reliable EQA system for D-dimer testing can be developed using pooled normal samples as a "low D-dimer sample" and samples modified by the addition of purified commercially prepared D-dimer as a "moderately elevated D-dimer sample" (as might be seen in patients with otherwise uncomplicated venous thromboembolism) or "markedly elevated D-dimer samples" (as might be seen in patients with disseminated intravascular coagulation). This EQA system can be applied to qualitative, semiquantitative, and quantitative assay systems. This observation suggests that such material should be made available more widely for EQA testing in other jurisdictions given the current lack of such material. Furthermore, when properly instructed, participants were able to report their results using a controlled set of prespecified SI units. This latter observation has the potential to simplify monitoring of D-dimer levels because it will reduce the confusion imparted by the current lack of consensus in units for the reporting of D-dimer levels. 
